Morphological Features Cardiac Muscles in Hyperparathyroidism
Keywords:
calcium, hyperphosphatemia, hypocalcemia, parathyroid hormone, hyperparathyroidism
Abstract
The goal of this research is to determine how variations in parathyroid gland functional activity affect the morphological intensity of the heart muscles. The dynamics of the genesis of cardiac muscles is disclosed, and changes in the structure and morphology of the heart's major vessels are researched, thanks to the findings of morphological research methods. The study's findings revealed a distinction between the hyperparathyroid patient's normal histological appearance of the heart's major arteries.
References
X. Jiang, “The role of m6A modification in the biological functions and diseases,” Signal Transduct Target Ther, vol. 6, no. 1, 2021, doi: 10.1038/s41392-020-00450-x.
J. A. Kanis, “European guidance for the diagnosis and management of osteoporosis in postmenopausal women,” Osteoporosis International, vol. 30, no. 1, pp. 3–44, 2019, doi: 10.1007/s00198-018-4704-5.
J. E. Compston, “Osteoporosis,” The Lancet, vol. 393, no. 10169, pp. 364–376, 2019, doi: 10.1016/S0140-6736(18)32112-3.
M. Muttenthaler, “Trends in peptide drug discovery,” Nat Rev Drug Discov, vol. 20, no. 4, pp. 309–325, 2021, doi: 10.1038/s41573-020-00135-8.
R. Eastell, “Pharmacological management of osteoporosis in postmenopausal women: An endocrine society clinical practice guideline,” Journal of Clinical Endocrinology and Metabolism, vol. 104, no. 5, pp. 1595–1622, 2019, doi: 10.1210/jc.2019-00221.
T. Komori, “Regulation of proliferation, differentiation and functions of osteoblasts by runx2,” Int J Mol Sci, vol. 20, no. 7, 2019, doi: 10.3390/ijms20071694.
L. Wang, “Therapeutic peptides: current applications and future directions,” Signal Transduct Target Ther, vol. 7, no. 1, 2022, doi: 10.1038/s41392-022-00904-4.
J. Liu, “Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities,” Signal Transduct Target Ther, vol. 7, no. 1, 2022, doi: 10.1038/s41392-021-00762-6.
M. Kuro-o, “The Klotho proteins in health and disease,” Nat Rev Nephrol, vol. 15, no. 1, pp. 27–44, 2019, doi: 10.1038/s41581-018-0078-3.
D. J. Drucker, “Advances in oral peptide therapeutics,” Nat Rev Drug Discov, vol. 19, no. 4, pp. 277–289, 2020, doi: 10.1038/s41573-019-0053-0.
M. A. Clynes, “The epidemiology of osteoporosis,” Br Med Bull, vol. 133, no. 1, pp. 105–117, 2020, doi: 10.1093/bmb/ldaa005.
P. M. Camacho, “American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis— 2020 Update Executive Summary,” Endocrine Practice, vol. 26, no. 5, pp. 564–570, 2020, doi: 10.4158/GL-2020-0524.
G. Simonneau, “Haemodynamic definitions and updated clinical classification of pulmonary hypertension,” European Respiratory Journal, vol. 53, no. 1, 2019, doi: 10.1183/13993003.01913-2018.
E. Driggin, “Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic,” J Am Coll Cardiol, vol. 75, no. 18, pp. 2352–2371, 2020, doi: 10.1016/j.jacc.2020.03.031.
K. N. Patel, “The American association of endocrine surgeons guidelines for the definitive surgical management of thyroid disease in adults,” Ann Surg, vol. 271, no. 3, 2020, doi: 10.1097/SLA.0000000000003580.
C. B. Johnston, “Osteoporosis in Older Adults,” Medical Clinics of North America, vol. 104, no. 5, pp. 873–884, 2020, doi: 10.1016/j.mcna.2020.06.004.
T. K. Chen, “Chronic Kidney Disease Diagnosis and Management: A Review,” JAMA - Journal of the American Medical Association, vol. 322, no. 13, pp. 1294–1304, 2019, doi: 10.1001/jama.2019.14745.
J. Jankowski, “Cardiovascular Disease in Chronic Kidney Disease Pathophysiological Insights and Therapeutic Options,” Circulation, vol. 143, no. 11, pp. 1157–1172, 2021, doi: 10.1161/CIRCULATIONAHA.120.050686.
R. Eastell, “Pharmacological management of osteoporosis in postmenopausal women: An endocrine society clinical practice guideline,” Journal of Clinical Endocrinology and Metabolism, vol. 104, no. 5, pp. 1595–1622, 2019, doi: 10.1210/jc.2019-00221.
A. D. Cohen, “B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma,” Journal of Clinical Investigation, vol. 129, no. 6, pp. 2210–2221, 2019, doi: 10.1172/JCI126397.
M. Ramos-Casals, “Immune-related adverse events of checkpoint inhibitors,” Nat Rev Dis Primers, vol. 6, no. 1, 2020, doi: 10.1038/s41572-020-0160-6.
D. Haffner, “Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia,” Nat Rev Nephrol, vol. 15, no. 7, pp. 435–455, 2019, doi: 10.1038/s41581-019-0152-5.
G. Treglia, “Diagnostic performance of choline PET for detection of hyperfunctioning parathyroid glands in hyperparathyroidism: a systematic review and meta-analysis,” Eur J Nucl Med Mol Imaging, vol. 46, no. 3, pp. 751–765, 2019, doi: 10.1007/s00259-018-4123-z.
L. Tondo, “Clinical use of lithium salts: guide for users and prescribers,” Int J Bipolar Disord, vol. 7, no. 1, 2019, doi: 10.1186/s40345-019-0151-2.
R. B. Conley, “Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition,” Journal of Bone and Mineral Research, vol. 35, no. 1, pp. 36–52, 2020, doi: 10.1002/jbmr.3877.
Avtsyn, A.P. Human trace elements: etiology, classification, organopathology / A.P. Avtsyn, A.A. Zhavoronkov, M.A. Rish, A.S. Strochkova. - M.: Medicine, 1991.- 496 p.
Khidirova G.O. World Bulletin of Public Health ISSN(E): 2749-3644, pp. 126-133.
Mikhailichenko V.Yu. Pathophysiological aspects of hypothyroidism in rats in an experiment / V.Yu. Mikhailichenko, V.A. Konoplyanko, O.V. Vasilyanskaya [et al.] // Bulletin of emergency and restorative medicine. - 2012. – Vol. 13, No. 1. – pp. 86-89.
Peppa M., Koliaki S., Nikolopoulos P., Raptis S.A.Insulin resistance of skeletal muscles in endocrine diseases. J.Biomed. Biotechnology. 2010; 2010. 527850.
Javed Z., Satyapalan T. Levothyroxine treatment of mild subclinical hypothyroidism: a review of potential risks and benefits. Ter. adv. Endocrinol. Metab. 2016; 7: 12-23.
J. A. Kanis, “European guidance for the diagnosis and management of osteoporosis in postmenopausal women,” Osteoporosis International, vol. 30, no. 1, pp. 3–44, 2019, doi: 10.1007/s00198-018-4704-5.
J. E. Compston, “Osteoporosis,” The Lancet, vol. 393, no. 10169, pp. 364–376, 2019, doi: 10.1016/S0140-6736(18)32112-3.
M. Muttenthaler, “Trends in peptide drug discovery,” Nat Rev Drug Discov, vol. 20, no. 4, pp. 309–325, 2021, doi: 10.1038/s41573-020-00135-8.
R. Eastell, “Pharmacological management of osteoporosis in postmenopausal women: An endocrine society clinical practice guideline,” Journal of Clinical Endocrinology and Metabolism, vol. 104, no. 5, pp. 1595–1622, 2019, doi: 10.1210/jc.2019-00221.
T. Komori, “Regulation of proliferation, differentiation and functions of osteoblasts by runx2,” Int J Mol Sci, vol. 20, no. 7, 2019, doi: 10.3390/ijms20071694.
L. Wang, “Therapeutic peptides: current applications and future directions,” Signal Transduct Target Ther, vol. 7, no. 1, 2022, doi: 10.1038/s41392-022-00904-4.
J. Liu, “Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities,” Signal Transduct Target Ther, vol. 7, no. 1, 2022, doi: 10.1038/s41392-021-00762-6.
M. Kuro-o, “The Klotho proteins in health and disease,” Nat Rev Nephrol, vol. 15, no. 1, pp. 27–44, 2019, doi: 10.1038/s41581-018-0078-3.
D. J. Drucker, “Advances in oral peptide therapeutics,” Nat Rev Drug Discov, vol. 19, no. 4, pp. 277–289, 2020, doi: 10.1038/s41573-019-0053-0.
M. A. Clynes, “The epidemiology of osteoporosis,” Br Med Bull, vol. 133, no. 1, pp. 105–117, 2020, doi: 10.1093/bmb/ldaa005.
P. M. Camacho, “American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis— 2020 Update Executive Summary,” Endocrine Practice, vol. 26, no. 5, pp. 564–570, 2020, doi: 10.4158/GL-2020-0524.
G. Simonneau, “Haemodynamic definitions and updated clinical classification of pulmonary hypertension,” European Respiratory Journal, vol. 53, no. 1, 2019, doi: 10.1183/13993003.01913-2018.
E. Driggin, “Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic,” J Am Coll Cardiol, vol. 75, no. 18, pp. 2352–2371, 2020, doi: 10.1016/j.jacc.2020.03.031.
K. N. Patel, “The American association of endocrine surgeons guidelines for the definitive surgical management of thyroid disease in adults,” Ann Surg, vol. 271, no. 3, 2020, doi: 10.1097/SLA.0000000000003580.
C. B. Johnston, “Osteoporosis in Older Adults,” Medical Clinics of North America, vol. 104, no. 5, pp. 873–884, 2020, doi: 10.1016/j.mcna.2020.06.004.
T. K. Chen, “Chronic Kidney Disease Diagnosis and Management: A Review,” JAMA - Journal of the American Medical Association, vol. 322, no. 13, pp. 1294–1304, 2019, doi: 10.1001/jama.2019.14745.
J. Jankowski, “Cardiovascular Disease in Chronic Kidney Disease Pathophysiological Insights and Therapeutic Options,” Circulation, vol. 143, no. 11, pp. 1157–1172, 2021, doi: 10.1161/CIRCULATIONAHA.120.050686.
R. Eastell, “Pharmacological management of osteoporosis in postmenopausal women: An endocrine society clinical practice guideline,” Journal of Clinical Endocrinology and Metabolism, vol. 104, no. 5, pp. 1595–1622, 2019, doi: 10.1210/jc.2019-00221.
A. D. Cohen, “B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma,” Journal of Clinical Investigation, vol. 129, no. 6, pp. 2210–2221, 2019, doi: 10.1172/JCI126397.
M. Ramos-Casals, “Immune-related adverse events of checkpoint inhibitors,” Nat Rev Dis Primers, vol. 6, no. 1, 2020, doi: 10.1038/s41572-020-0160-6.
D. Haffner, “Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia,” Nat Rev Nephrol, vol. 15, no. 7, pp. 435–455, 2019, doi: 10.1038/s41581-019-0152-5.
G. Treglia, “Diagnostic performance of choline PET for detection of hyperfunctioning parathyroid glands in hyperparathyroidism: a systematic review and meta-analysis,” Eur J Nucl Med Mol Imaging, vol. 46, no. 3, pp. 751–765, 2019, doi: 10.1007/s00259-018-4123-z.
L. Tondo, “Clinical use of lithium salts: guide for users and prescribers,” Int J Bipolar Disord, vol. 7, no. 1, 2019, doi: 10.1186/s40345-019-0151-2.
R. B. Conley, “Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition,” Journal of Bone and Mineral Research, vol. 35, no. 1, pp. 36–52, 2020, doi: 10.1002/jbmr.3877.
Avtsyn, A.P. Human trace elements: etiology, classification, organopathology / A.P. Avtsyn, A.A. Zhavoronkov, M.A. Rish, A.S. Strochkova. - M.: Medicine, 1991.- 496 p.
Khidirova G.O. World Bulletin of Public Health ISSN(E): 2749-3644, pp. 126-133.
Mikhailichenko V.Yu. Pathophysiological aspects of hypothyroidism in rats in an experiment / V.Yu. Mikhailichenko, V.A. Konoplyanko, O.V. Vasilyanskaya [et al.] // Bulletin of emergency and restorative medicine. - 2012. – Vol. 13, No. 1. – pp. 86-89.
Peppa M., Koliaki S., Nikolopoulos P., Raptis S.A.Insulin resistance of skeletal muscles in endocrine diseases. J.Biomed. Biotechnology. 2010; 2010. 527850.
Javed Z., Satyapalan T. Levothyroxine treatment of mild subclinical hypothyroidism: a review of potential risks and benefits. Ter. adv. Endocrinol. Metab. 2016; 7: 12-23.
Published
2024-03-06
How to Cite
Khidirova, G. O. (2024). Morphological Features Cardiac Muscles in Hyperparathyroidism. Central Asian Journal of Medical and Natural Science, 5(1), 679-683. Retrieved from https://cajmns.centralasianstudies.org/index.php/CAJMNS/article/view/2393
Section
Articles
